DOCSLIB.ORG

NICE UPDATE for COMMISSIONERS November 2020

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

South, Central and West NICE UPDATE FOR COMMISSIONERS November 2020 This NICE Update for Commissioners includes: Coronavirus (COVID-19) guidance NICE published rapid guidelines and evidence reviews At-a-glance summary Headline update: what’s been published? Guidance and quality standards published by NICE in November 2020 What’s new for CCGs? Horizon scanning What’s coming out from NICE in the next six months? NICE guidance in consultation What NICE guidance is in consultation? For your reference, a summary of the types of NICE guidance Reference – a guide to NICE products The next (December 2020) NICE Update for Commissioners will be issued at the beginning of January 2021. For further information about NICE guidance and its implementation contact: Tiina Korhonen, Clinical Effectiveness Lead Kim Tie, Clinical Effectiveness Manager Kathryn Markey, Clinical Effectiveness Manager Katie Newens, Clinical Effectiveness Researcher Kate Forbes, Clinical Effectiveness Manager Rachel Finch, Clinical Effectiveness Administrator Rebecca Hodge, Clinical Effectiveness Manager Helen Hicks, Clinical Effectiveness Administrator Jenny Kovalaine-Kwan, Clinical Effectiveness Manager [email protected] SCWCSU/Clinical effectiveness/v1.0 Page 1 of 20 NICE Coronavirus (COVID-19) Rapid guidelines and evidence reviews NICE is currently developing and updating rapid guidelines and evidence reviews to support the NHS and social care to respond quickly to the challenges of the coronavirus pandemic. Rapid guidelines are developed in collaboration with NHS England and NHS Improvement and a cross-speciality clinical group, supported by the specialist societies and royal colleges. These guidelines are developed using the NICE interim process and methods for developing rapid guidelines on COVID-19. Rapid evidence reviews will look at whether certain medicines or treatments may affect the severity or length of COVID-19 illness. NICE is also working with the Medicines and Healthcare products Regulatory Agency (MHRA) to facilitate rapid review of information and advice on the safety and efficacy of treatments for COVID-19. The following COVID rapid guidelines have been published or updated: Guidance type and Title Overview reference COVID-19 rapid COVID-19 rapid guideline: In this update, NICE removed the option to defer treatments that prevent long-term guideline NG161 delivery of systemic anticancer complications, and amended guidance on treatments suitable for home delivery. Update treatments COVID-19 rapid COVID-19 rapid guideline: This guideline covers pharmacological VTE prophylaxis for patients being treated for guideline NG186 reducing the risk of venous COVID-19 pneumonia. It includes patients receiving treatment in hospital or in a thromboembolism (VTE) in community setting such as a ‘hospital at home’ service or COVID-19 ‘virtual ward’. over 16s with COVID-19 The guideline applies to all patients with COVID-19 pneumonia, including those who have other conditions. For guidance on VTE prophylaxis for hospital patients who do not have COVID-19 pneumonia, see the NICE guideline NG89 on venous thromboembolism in over 16s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism. SCWCSU/Clinical effectiveness/v1.0 Page 2 of 20 At-a-glance summary The table below shows all NICE guidance published in November 2020. New guidelines, or those likely to have a significant impact for CCG commissioners, are discussed further in the ‘What’s new for Clinical Commissioning Groups’ section (link to relevant section provided within guidance reference). Guidance type and Title Commissioner(s) Main providers(s) Impact for CCG commissioners (financial reference /public interest/quality of care) Technology appraisal Guidance on the use of NHS England and Secondary care Recommendation 1.1 was updated to be in guidance TA71 Update coronary artery stents CCGs line with the recently published NICE guideline on acute coronary syndromes. See NICE guideline NG185 below for more details. Technology appraisal Drug-eluting stents for the NHS England and Secondary care Recommendation 1.1 was updated to be in guidance TA152 treatment of coronary artery CCGs line with the recently published NICE Update disease guideline on acute coronary syndromes. See NICE guideline NG185 below for more details. Technology appraisal Siponimod for treating NHS England Secondary care guidance TA656 secondary progressive multiple sclerosis Technology appraisal Carfilzomib for previously NHS England Secondary care guidance TA657 treated multiple myeloma Technology appraisal Isatuximab with NHS England Secondary care guidance TA658 pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma Technology appraisal Galcanezumab for CCGs Secondary care NICE estimates that potential savings can be guidance TA659 preventing migraine made in the form of: reduced GP appointments and burden on acute healthcare SCWCSU/Clinical effectiveness/v1.0 Page 3 of 20 Guidance type and Title Commissioner(s) Main providers(s) Impact for CCG commissioners (financial reference /public interest/quality of care) providers, improved clinic capacity due to reduced uptake of botulinum toxin A; reduced use of triptans; and reduction in economic burden through reducing frequency of migraine days. Technology appraisal Darolutamide with androgen NHS England Secondary care guidance TA660 deprivation therapy for treating hormone-relapsed non-metastatic prostate cancer Technology appraisal Pembrolizumab for NHS England Secondary care guidance TA661 untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma Technology appraisal Durvalumab in combination Terminated appraisal guidance TA662 for untreated extensive- stage small-cell lung cancer NICE Guideline NG184 Human and animal bites: CCGs Primary care and This guideline aims to optimise antibiotic use antimicrobial prescribing Secondary care and reduce antibiotic resistance. Although NICE have not produced an impact report or statement for this guideline, it is possible that savings may arise from a reduction in antibiotic prescribing and complications associated with antibiotic resistance. SCWCSU/Clinical effectiveness/v1.0 Page 4 of 20 Guidance type and Title Commissioner(s) Main providers(s) Impact for CCG commissioners (financial reference /public interest/quality of care) NICE Guideline NG185 Acute coronary syndromes NHS England and Primary care and There are 4 recommendations which are CCGs Secondary care likely to lead to a significant resource impact when implemented: Offer prasugrel as part of dual antiplatelet therapy with aspirin to people with acute ST-elevation myocardial infarction (STEMI) intended for treatment with primary percutaneous coronary intervention (PCI); Offer complete revascularisation with PCI for people with acute STEMI and multivessel coronary artery disease; Offer prasugrel or ticagrelor, as part of dual antiplatelet therapy with aspirin, to people with unstable angina and non-ST elevated myocardial infarction (NSTEMI) who are having coronary angiography; Offer ticagrelor, as part of dual antiplatelet therapy with aspirin, to people with unstable angina and NSTEMI when PCI is not indicated, unless they have a high bleeding risk. NICE Quality Standard Acute coronary syndromes NHS England and Primary care and Changes have been made to align this quality QS68 Update in adults CCGs Secondary care standard with the updated NICE guideline on acute coronary syndromes. Statement 3 was amended to reflect that not all people in this group will have early invasive intervention, in line with the updated recommendations. The source guidance and references were also updated. SCWCSU/Clinical effectiveness/v1.0 Page 5 of 20 Interventional Procedures Guidelines Type of Guidance and Title Recommendation reference Interventional Swallowable gastric balloon Evidence on the safety of the swallowable gastric balloon capsule for weight loss procedures guidance capsule for weight loss shows infrequent but potentially serious adverse events: IPG684 For people who need to lose weight in the short term for medical reasons, the evidence of efficacy is adequate to support the use of this procedure provided that special arrangements are in place for clinical governance, consent and audit. For people who are aiming for long-term weight loss, the evidence on efficacy is inadequate in quantity and quality, so the procedure should only be used in the context of research. What’s new for Clinical Commissioning Groups? Technology Appraisals Galcanezumab for preventing migraine https://www.nice.org.uk/guidance/ta659 Elevated calcitonin gene-related peptide (CGRP) blood concentrations have been associated with migraine attacks. Galcanezumab is a humanised IgG4 monoclonal antibody that binds with CGRP, thus preventing its biological activity. Galcanezumab is recommended as an option for preventing migraine in adults, only if: they have 4 or more migraine days a month at least 3 preventive drug treatments have failed and the company provides it according to the commercial arrangement. Treatment with galcanezumab should be stopped after 12 weeks if: in episodic migraine (less than 15 headache days a month) the frequency does not reduce by at least 50% in chronic migraine (15 headache days a month or more with at least 8 of those having features of migraine) the frequency does not reduce by at least 30%. Galcanezumab is available as a once monthly injection which can be self-administered.
Recommended publications
  • Skin Care, Insect Bites and Stings

    Skin Care, Insect Bites and Stings

    DEPARTMENT KLINISCHE WETENSCHAPPEN | MEDISCHE DIENSTEN Kronenburgstraat 43/3, 2000 Antwerpen | Fax: +32 3 247 64 10 Updated version (20/05/2015 – AVG) see: www.travelhealth.be SKIN CARE, INSECT BITES AND STINGS Sun The closer you get to the Equator, the more intense sunlight becomes. Sunbathing in the tropics has to be done in moderation. Protective clothing and hats are recommended. Apply sun cream with high sun protection factor (30 or more) to exposed skin regularly (every two hours) and carefully. Apply sun cream after bathing and avoid long water exposure since sun stroke will be imminent in spite of reduced heat feeling. Avoid perfumed sun creams and check whether or not used creams or medication can cause "sun allergy" (photo-toxic or photo-allergic reactions). We would like to refer to point 5 of the European cancer code: avoid excessive exposure to sun and sunburn during childhood (increased risk of melanomas in later life). Do not take a course of sunbed sessions before going on holiday as the sun tan obtained through UV-A does not give any extra protection against the natural UV-rays. When using sun creams and insect repellents based on DEET, recent studies have shown that DEET reduces the effectiveness of the sun cream, but that sun creams do not have a negative influence on the effectiveness of DEET. It is advisable, therefore, to apply the insect repellent (DEET or another repellent) with the sun lotion and then to take additional precautions to protect against UV (e.g. a sun cream with a higher protection factor).
  • Allergic Reactions to Bites and Stings

    Allergic Reactions to Bites and Stings

    Allergic Reactions to Bites and Stings ASCIA EDUCATION RESOURCES (AER) PATIENT INFORMATION Most insect bites and stings result in a localised itch and swelling that settles within a few days. Severe allergic reactions (anaphylaxis) to insects are relatively uncommon, and are usually due to bees, wasps or the Australian Jack Jumper ant. Fortunately, effective treatments are available to treat allergic reactions to bites and stings. Stinging insects are a common cause of anaphylaxis Allergies to venoms from stinging insects are one of the most common causes of severe allergic reactions (anaphylaxis) in Australia. Symptoms include an all over rash, swelling of tongue or throat, trouble breathing, gut cramps, diarrhoea, vomiting or even a drop in blood pressure (shock). Although the insects are all hymenoptera (which means membranous winged insects), their venoms are very different. Allergy to one type of stinging insect does not usually increase the risk of reaction to another. The Honey Bee is the most common cause of allergic reactions in Australia. Paper Wasps and European Wasps can sting multiple times. The European Wasp is becoming an increasing problem in Australia, is particularly aggressive and likes to get inside drink cans at barbeques, although the more familiar Paper Wasp is responsible for the majority of serious stings. The Australian Jack Jumper Ant (Myrmecia pilosula) is a medium sized black bull ant prevalent down the eastern side of Australia and Tasmania. It can be recognised by its characteristic hopping motion when it walks. It is a very aggressive ant and its sting can cause severe local pain. Severe allergic reactions are much more common than is seen with more common bull ants.
  • DRUGS REQUIRING PRIOR AUTHORIZATION in the MEDICAL BENEFIT Page 1

    DRUGS REQUIRING PRIOR AUTHORIZATION in the MEDICAL BENEFIT Page 1

    Effective Date: 08/01/2021 DRUGS REQUIRING PRIOR AUTHORIZATION IN THE MEDICAL BENEFIT Page 1 Therapeutic Category Drug Class Trade Name Generic Name HCPCS Procedure Code HCPCS Procedure Code Description Anti-infectives Antiretrovirals, HIV CABENUVA cabotegravir-rilpivirine C9077 Injection, cabotegravir and rilpivirine, 2mg/3mg Antithrombotic Agents von Willebrand Factor-Directed Antibody CABLIVI caplacizumab-yhdp C9047 Injection, caplacizumab-yhdp, 1 mg Cardiology Antilipemic EVKEEZA evinacumab-dgnb C9079 Injection, evinacumab-dgnb, 5 mg Cardiology Hemostatic Agent BERINERT c1 esterase J0597 Injection, C1 esterase inhibitor (human), Berinert, 10 units Cardiology Hemostatic Agent CINRYZE c1 esterase J0598 Injection, C1 esterase inhibitor (human), Cinryze, 10 units Cardiology Hemostatic Agent FIRAZYR icatibant J1744 Injection, icatibant, 1 mg Cardiology Hemostatic Agent HAEGARDA c1 esterase J0599 Injection, C1 esterase inhibitor (human), (Haegarda), 10 units Cardiology Hemostatic Agent ICATIBANT (generic) icatibant J1744 Injection, icatibant, 1 mg Cardiology Hemostatic Agent KALBITOR ecallantide J1290 Injection, ecallantide, 1 mg Cardiology Hemostatic Agent RUCONEST c1 esterase J0596 Injection, C1 esterase inhibitor (recombinant), Ruconest, 10 units Injection, lanadelumab-flyo, 1 mg (code may be used for Medicare when drug administered under Cardiology Hemostatic Agent TAKHZYRO lanadelumab-flyo J0593 direct supervision of a physician, not for use when drug is self-administered) Cardiology Pulmonary Arterial Hypertension EPOPROSTENOL (generic)
  • Avoiding and Treating Work-Related Insect Bites and Stings

    Avoiding and Treating Work-Related Insect Bites and Stings

    FACT SHEET Avoiding and Treating Work-Related Insect Bites and Stings This WorkCare Fact Sheet describes work-related bite and sting risks, symptoms, treatment and preventive measures. Bites and stings are a relatively common occurrence for people who work outdoors and in enclosed environments where bees and wasps, fire ants, insects and arachnids (spiders, scorpions, ticks and mites) feel at home. Employers and workers are encouraged to understand exposure risks, how to recognize and respond to stings and bites, and what they can do to prevent them. Under 29 CFR Part 1904 – Recording and Reporting Occupational Injuries and Illnesses, the Occupational Safety and Health Administration (OSHA) considers bites and stings to be recordable when an employee who is bitten or stung while working receives medical treatment beyond first aid. First aid is defined in1904.7 (b)(5)(ii). Exposure Risk Thousands of people in the U.S. are stung or bitten each year. Exposed arms and hands tend to be more susceptible to stings and bites among workers than legs and feet, which are usually protected by clothing and enclosed shoes. In a study of occupationally related bites and stings, the head, one of the most exposed body parts, accounted for one-tenth of cases involving insects and arachnids; a third of those cases affected the eyes. An estimated 90 to 100 people die each year in the U.S. as a result of allergic reactions to bites and stings. Overall, bite- and sting-related injuries and fatalities may be misdiagnosed as heart attack or sunstroke, or attributed to other causes, according to the National Institute for Occupational Safety and Health (NIOSH).
  • Galcanezumab-Gnlm) Injection, for Subcutaneous Use

    Galcanezumab-Gnlm) Injection, for Subcutaneous Use

    1 HIGHLIGHTS OF PRESCRIBING INFORMATION • Administer in the abdomen, thigh, back of the upper arm, or These highlights do not include all the information needed to use buttocks subcutaneously. (2.3) EMGALITY safely and effectively. See full prescribing information for EMGALITY. ---------------------- DOSAGE FORMS AND STRENGTHS --------------------­ • Injection: 120 mg/mL solution in a single-dose prefilled pen (3) EMGALITY (galcanezumab-gnlm) injection, for subcutaneous use Initial U.S. Approval: 2018 • Injection: 120 mg/mL solution in a single-dose prefilled syringe (3) • Injection: 100 mg/mL solution in a single-dose prefilled syringe (3) --------------------------- RECENT MAJOR CHANGES -------------------------­ Indications and Usage, Episodic Cluster Headache (1.2) 06/2019 ------------------------------- CONTRAINDICATIONS -----------------------------­ Dosage and Administration, Recommended Dosing for Episodic EMGALITY is contraindicated in patients with serious hypersensitivity Cluster Headache (2.2) 06/2019 to galcanezumab-gnlm or to any of the excipients. (4) ---------------------------- INDICATIONS AND USAGE --------------------------­ ------------------------ WARNINGS AND PRECAUTIONS ----------------------­ EMGALITY® is a calcitonin-gene related peptide antagonist indicated in Hypersensitivity Reactions: If a serious hypersensitivity reaction adults for the: occurs, discontinue administration of EMGALITY and initiate appropriate therapy. Hypersensitivity reactions could occur days after • preventive treatment of migraine. (1.1)
  • Unit 3 Bites and Stings

    Unit 3 Bites and Stings

    First Aid in Common and Environmental Emergencies UNIT 3 BITES AND STINGS Structure 3.0 Introduction 3.1 Objectives 3.2 Bites and Stings 3.2.1 Definition, Causes, Types and Recognition of Bites and Stings 3.2.2 Assessment of the Victim and General First Aid 3.3 Various Bites/Stings 3.3.1 Scorpion Bite and Spider Bite 3.3.2 Snake Bite 3.3.3 Insect Bite 3.3.4 Animal Bites (Dog Bite/Monkey Bites) 3.3.5 Human Bites 3.4 Let Us Sum Up 3.5 Keywords 3.6 Answers to Check Your Progress 3.7 References and Further Readings 3.0 INTRODUCTION Bites and stings are commonly seen in the rural and remote areas. Nowadays, however, they can occur in urban areas also. Lakhs of people every year are bitten or stung by someone or something. These emergencies include bites and stings due to various reasons. These bites or stings need to be identified and treated early as they affect some part or the whole of the body which can cause mild, moderate or severe reaction and can even be life-threatening. Most are not medical emergencies but however, treatment is usually required if there is bleeding, wounds or infection. All bites and stings are not same. Different First Aid treatment and care is needed depending on the type of insect or animal that has caused the bite. Some species are more dangerous and cause more harm compared to others. Hence, in this unit we shall discuss the different types of bites and stings, causes, recognition and first aid in these situations.
  • Wasp Sting Envenomation - a Case Report

    Wasp Sting Envenomation - a Case Report

    Forensic Research & Criminology International Journal Case Report Open Access Wasp sting envenomation - a case report Abstract Volume 4 Issue 6 - 2017 Wasps belonging to the family vespidae is one of the dangerous hymenopteran when 1 2 3 disturbed in its habitat either accidently or purposely. Wasp stings are common, especially Badiadka KK, Amir S, Pramod KL 1Associate Professor, Department of Forensic Medicine, in populations living in vicinity to forested areas all over the world. Local signs following Yenepoya Medical College, India stings are common and generally life threatening anaphylaxis may occur, including Kounis 2Postgraduate, Department of Forensic Medicine, Yenepoya syndrome requiring immediate treatment. This case report is of a 67 yr old woman bitten Medical College, India by a swarm of wasps leading to her death due to envenomation and related complications. 3Curator, Department of Forensic Medicine, Yenepoya Medical College, India Keywords: wasp sting, hymenopteran, anaphylaxis, kounis syndrome, envenomation Correspondence: K Leena Pramod, Curator, Department of Forensic Medicine, Yenepoya Medical College, Deralakatte, Mangalore, India, Tel 91 9449366780, Email Received: May 01, 2017 | Published: May 12, 2017 Introduction was an early summer season and a very humid day. The scene was a house under construction, with a front area covered with fallen leaves The Phylum Arthropoda constitutes more than 50% of animal and a big tree. The tree was on edge of ground with roots exposed on species found on earth, of which the insects, spiders belonging to one side. The exposed area was burnt and ash was seen near it (Figure 1 the order Hymenoptera are the main cause for human mortality.
  • 761063Orig1s000

    761063Orig1s000

    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 761063Orig1s000 CLINICAL PHARMACOLOGY AND BIOPHARMACEUTICS REVIEW(S) Office of Clinical Pharmacology Review BLA Number 761063 Link to EDR \\cdsesub1\evsprod\bla761063\0001\m1\us\cover.pdf Submission Date 10/27/2017 Submission Type NME, Standard Review Brand Name EMGALITYTM Generic Name Galcanezumab Dosage Form and Strength 120 mg/mL Prefilled auto-injector pen and Pre-filled syringe Route of Administration Subcutaneous injection Proposed Dose/Regimen: 120 mg once monthly, with a 240 mg loading dose as the initial dose Proposed Indication preventive treatment of migraine Applicant Eli Lilly and Company Associated IND 111295 OCP Review Team Bilal AbuAsal, Ph.D., Gopichand Gottipati, Ph.D., Kevin Krudys, Ph.D., Sreedharan Sabarinath, Ph.D. OCP Final Signatory Ramana Uppoor, Ph.D. 1 Reference ID: 4278873 Table of Contents 1. EXECUTIVE SUMMARY .......................................................................................................................... 3 1.1 Recommendations ........................................................................................................................ 3 1.2 Post-Marketing Requirements and Commitments ....................................................................... 4 2. SUMMARY OF CLINICAL PHARMACOLOGY ASSESSMENT ..................................................................... 5 2.1 Pharmacology and Clinical Pharmacokinetics............................................................................... 5 2.2 Dosing and
  • Transcriptional Inhibition of Hypertrophic Scars by a Gene

    Transcriptional Inhibition of Hypertrophic Scars by a Gene

    ORIGINAL ARTICLE Transcriptional Inhibition of Hypertrophic Scars by a Gene Silencer, Pyrrole–Imidazole Polyamide, Targeting the TGF-b1 Promoter Hisayo Washio1, Noboru Fukuda2, Hiroyuki Matsuda2, Hiroki Nagase3, Takayoshi Watanabe3, Yoshiaki Matsumoto4 and Tadashi Terui1 Synthetic pyrrole–imidazole (PI) polyamides bind to the minor groove of double-helical DNA with high affinity and specificity, and inhibit the transcription of corresponding genes. We examined the effects of a transforming growth factor (TGF)-b1-targeted PI polyamide (Polyamide) on hypertrophic skin scars in rats. Hypertrophic scars were created dorsally in rats by incisions. FITC-labeled Polyamide was injected to investigate its distribution in the skin. Expression of TGF-b1, connective tissue growth factor (CTGF), collagen type1, and fibronectin mRNAs was evaluated by reverse transcription PCR analysis. The extent of fibrosis and the expression of TGF-b1 were evaluated histologically and immunohistochemically. Polyamide was distributed in almost all nuclei of skin cells. Expression of TGF-b1 mRNA reached a peak at 3 days after skin incision. Expression of CTGF and extracellular matrix mRNAs was increased continuously even after the peak induction of TGF-b1 mRNA. Injection of Polyamide completely inhibited both the development of scars and the induction of growth factors and extracellular matrix mRNAs. The treatment also markedly inhibited fibrotic changes and reduced the numbers of vimentin-positive spindle-shaped fibroblasts. Injection of Polyamide also reduced established
  • Immunfarmakológia Immunfarmakológia

    Immunfarmakológia Immunfarmakológia

    Gergely: Immunfarmakológia Immunfarmakológia Prof Gergely Péter Az immunpatológiai betegségek döntő többsége gyulladásos, és ennek következtében általában szövetpusztulással járó betegség, melyben – jelenleg – a terápia alapvetően a gyulladás csökkentésére és/vagy megszűntetésére irányul. Vannak kizárólag gyulladásgátló gyógyszereink és vannak olyanok, amelyek az immunreakció(k) bénításával (=immunszuppresszió révén) vagy emellett vezetnek a gyulladás mérsékléséhez. Mind szerkezetileg, mind hatástanilag igen sokféle csoportba oszthatók, az alábbi felosztás elsősorban didaktikus célokat szolgál. 1. Nem-szteroid gyulladásgátlók (‘nonsteroidal antiinflammatory drugs’ NSAID) 2. Kortikoszteroidok 3. Allergia-elleni szerek (antiallergikumok) 4. Sejtoszlás-gátlók (citosztatikumok) 5. Nem citosztatikus hatású immunszuppresszív szerek 6. Egyéb gyulladásgátlók és immunmoduláns szerek 7. Biológiai terápia 1. Nem-szteroid gyulladásgátlók (NSAID) Ezeket a vegyületeket, melyek őse a szalicilsav (jelenleg, mint acetilszalicilsav ‘aszpirin’ használatos), igen kiterjedten alkalmazzák a reumatológiában, az onkológiában és az orvostudomány szinte minden ágában, ahol fájdalom- és lázcsillapításra van szükség. Egyes felmérések szerint a betegek egy ötöde szed valamilyen NSAID készítményt. Szerkezetük alapján a készítményeket több csoportba sorolhatjuk: szalicilátok (pl. acetilszalicilsav) pyrazolidinek (pl. fenilbutazon) ecetsav származékok (pl. indometacin) fenoxiecetsav származékok (pl. diclofenac, aceclofenac)) oxicamok (pl. piroxicam, meloxicam) propionsav
  • Notes to General Risk Assessment Form RA1

    Notes to General Risk Assessment Form RA1

    Produced by the Health and Safety Department, the University of Edinburgh Health Risks from Working Outdoors: There are several health hazards which may affect people who work outdoors. Some of the main hazards which people may be exposed to include: Exposure to UV radiation from the sun: UV radiation from the sun causes damage to skin. The main effects include sunburn, blistering, skin ageing, an in the long term may lead to skin cancer. Skin cancer is the most common from of cancer in the UK, with over 40,000 new cases diagnosed each year. There are three main types of skin cancer: 1. Basal cell carcinoma (rodent ulcer) This type of cancer is usually found in people over 60. It is often linked with years of working outdoors, outdoor sports, or life in the tropics. The most likely sites are on the face and hair bearing skin. Appearance may vary, but there is often a nodule which slowly grows to 0.5cm over a couple of years. It may look translucent or pigmented, and may develop a raised pearly border with a non-healing ulcer in the centre. This type of cancer does not usually spread to form secondary cancers, however early treatment is vital to prevent extensive tissue damage around the site of the cancer. 2. Squamous cell carcinoma This type of skin cancer mainly occurs in older people usually following long exposure to UV radiation as in outdoor work. Appearance is usually of a warty lump, nodule, ulcer, or sore which does not heal. Squamous cell carcinomas also have a very high cure rate, but early treatment is vital in order to prevent tissue damage.
  • Causes and Effective Management of Insect Bites in the UK

    Causes and Effective Management of Insect Bites in the UK

    KNOWLEDGE WOUND CARE SUPPLEMENT Marion Richardson, BD, CertEd, RGN, RNT, DipN, is senior lecturer Causes and effective management and programme leader, emergency of insect bites in the UK nursing, University of Hertfordshire Insects play an important role in maintaining the site of bites and, worldwide, mosquitoes transmit Marion Richardson describes world’s ecosystem (Zhu and Stiller, 2002) but many diseases from one bitten host to the next. These include the causes of insect bites of them feed on other animals. Humans are relatively malaria, yellow fever, dengue fever (acute arbovirus and the management of this hairless and provide an easy target, especially when infection), lymphatic filariasis (caused by the lymphatic uncomfortable problem partly clothed (Cohn, 2003). Biting insects common filarial parasites), and encephalitis (Zhu and Stiller, 2002). to the UK include midges, gnats, mosquitoes, flies, West Nile virus is the most likely mosquito-borne fleas, lice, mites, ticks, and bedbugs (Fig 1). disease in the UK. It is uncommon because the KEY WORDS population density of mosquitoes is relatively low Insects Although their bites rarely cause serious problems, the (Prodigy, 2003). In most people the infection is Bites salivary gland excretions they deposit contain various asymptomatic or causes a mild influenza-like illness. It Inflammation antigenic substances that may provoke a reaction in may cause encephalitis or aseptic meningitis, especially susceptible people (Prodigy, 2003). in people aged over 50 (Prodigy, 2003; Crook et al, 2002). Insect habits and habitats Midges Only female midges attack, often in swarms at Bedbugs These are nocturnal blood-sucking parasites sunrise or sunset and with a higher frequency in that feed at night.